Depemokimab’s PDUFA date is set for December 16, 2025, with FDA reviewing two indications. Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Markets are ...

The proposed indications are as add-on maintenance treatment of asthma in adult and paediatric patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype on ...

Chimerix has another clinical candidate, ONC206, which is being evaluated in early-stage, dose-escalating studies ... by an eosinophilic phenotype on medium to high-dose inhaled corticosteroids ...

Several single-dose studies comparing acute bronchodilation ... airway smooth muscle and of the mucous bronchial glands in the medium-to-large airways, with subsequent bronchoconstriction and ...

Among patients taking medium- or high-dose inhaled corticosteroids (ICs), the Paxlovid group was at lower risk for asthma exacerbation than molnupiravir recipients (HR, 0.58). A subgroup analysis ...

med.uni-heidelberg.de Objective: To systematically review the evidence for the medium to long term benefits and risks ... including constant or tapered doses of ICS, compared montelukast/ICS with ICS ...

Demand for medical ICs used inside and outside the body is growing rapidly, but unique manufacturing and functional requirements coupled with low volumes have turned this into a complex and extremely ...

Mouser Electronics, Inc. is now stocking radiation-hardened low Earth orbit (LEO) A-Grade ICs from Apogee Semiconductor.